TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36007481

Group type: EXPERIMENTAL
Intervention: In-person follow-up
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Text message follow-up
Number of subjects: 208
Study: 34967883

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg every 6 months)
Number of subjects: 3936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3936

Group type: EXPERIMENTAL
Intervention: Azithromycin (for children in the shortest quartile of baseline height)
Number of subjects: 3936

Group type: COMPARATOR
Intervention: Placebo (for children in the shortest quartile of baseline height)
Number of subjects: 3936
Study: 35706460

Group type: EXPERIMENTAL
Intervention: Green tea consumption for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phase 1 periodontal treatment (scaling and root planning)
Number of subjects: 30
Study: 32841846

Group type: EXPERIMENTAL
Intervention: 1 h of bright light (10,000 lux) exposure
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1 h of dim light (<300 lux) exposure
Number of subjects: 30
Study: 35956366

Group type: EXPERIMENTAL
Intervention: WB+KFsug + kiwifruit organic acids (WB+KFsug+OA)
Number of subjects: 9
Study: 33555464

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 33
Study: 32716280

Group type: EXPERIMENTAL
Intervention: MedBIKE™ high-intensity interval training
Number of subjects: 10
Study: 32886532

Group type: EXPERIMENTAL
Intervention: Robotic locomotor training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Activity-based intervention
Number of subjects: 16
Study: 32351156

Group type: EXPERIMENTAL
Intervention: Eye drop booklet
Number of subjects: 370

Group type: COMPARATOR
Intervention: No eye drop booklet (control group)
Number of subjects: 370
Study: 34813505

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 12
Study: 34379442

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance-prophylactic cranial irradiation (HA-PCI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard prophylactic cranial irradiation (PCI; 25 Gy in 10 fractions)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HA-PCI
Number of subjects: 150

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 150
Study: 32347899

Group type: EXPERIMENTAL
Intervention: Degarelix acetate (120 mg, 2 subcutaneous injections)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (equal volume to degarelix)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Degarelix acetate
Number of subjects: 52
Study: 35689985

Group type: EXPERIMENTAL
Intervention: Oxytocin intranasally
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32340974

Group type: EXPERIMENTAL
Intervention: Blockchain-based data management system for clinical trials
Number of subjects: 0
Study: 34340135

Group type: EXPERIMENTAL
Intervention: Cluster 1: no/low maltreatment, low trauma
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cluster 2: moderate physical and emotional abuse, moderate trauma
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cluster 3: moderate-severe maltreatment, low trauma
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cluster 4: severe maltreatment, high trauma
Number of subjects: 96
Study: 35034024

Group type: EXPERIMENTAL
Intervention: REACT (renal autologous cell therapy) administered via direct kidney parenchymal injection, 2 injections 6 months apart, with computed tomography guidance.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard of care (deferred treatment group) for 12 months before crossing over to receive REACT.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: REACT (renal autologous cell therapy)
Number of subjects: 83
Study: 32974775

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + connective tissue graft (CAF + CTG)
Number of subjects: 48
Study: 35040392

Group type: EXPERIMENTAL
Intervention: Larger assortments of choices
Number of subjects: 3549
Study: 34402076

Group type: EXPERIMENTAL
Intervention: Negative pressure irrigation (NPI) at -5 kPa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative pressure irrigation (NPI) at -10 kPa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative pressure irrigation (NPI) at -15 kPa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional irrigation (CK)
Number of subjects: 0
Study: 32341386

Group type: EXPERIMENTAL
Intervention: Indoor incense burning (self-reported use ≥ weekly over the past 5 years)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Indoor incense burning
Number of subjects: 515
Study: 34740676

Group type: EXPERIMENTAL
Intervention: Financial Incentives (FIM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Campaign (CAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (MCM)
Number of subjects: 0
Study: 33933130

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy
Number of subjects: 621

Group type: COMPARATOR
Intervention: Basic implementation strategy
Number of subjects: 621
Study: 32671948

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation at a dose of 1.5 × 10^8 cfu/kg in heat-stressed broilers.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Basal diet without probiotic in heat-stressed broilers (Control).
Number of subjects: 180

Group type: COMPARATOR
Intervention: Thermoneutral conditions with basal diet (Control).
Number of subjects: 180
Study: 34406877

Group type: EXPERIMENTAL
Intervention: ID-HWS1000
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32145739

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (working memory training, biofeedback and relaxation training, episodic future thinking training) over an 8-week period
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 94
Study: 36212437

Group type: EXPERIMENTAL
Intervention: Zaltoprofen (480 mg/day) for 48 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (similar dosages without zaltoprofen) for 48 weeks
Number of subjects: 41
Study: 32899368

Group type: EXPERIMENTAL
Intervention: acute treatment (wearing a mouthguard)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: repeated treatments (8 weeks follow‐up)
Number of subjects: 23
Study: 33565827

Group type: EXPERIMENTAL
Intervention: Laser-assisted rhinoplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classic rhinoplasty
Number of subjects: 50
Study: 35390540

Group type: EXPERIMENTAL
Intervention: Sociodrama-based communication enhancement program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 34486302

Group type: EXPERIMENTAL
Intervention: Milling process (T1, T2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reagent washing (T3, T4, T5, T6, T7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-processed grains (Control T9)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alkaline solution washing (T4)
Number of subjects: 0
Study: 35089874

Group type: EXPERIMENTAL
Intervention: Self-management program plus routine postoperative care
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine postoperative care only
Number of subjects: 95
Study: 33355910

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg (multiple dose for 10 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32120018

Group type: EXPERIMENTAL
Intervention: 150 mg testosterone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 140
Study: 35973791

Group type: EXPERIMENTAL
Intervention: Early GDM screening (14-20 weeks' gestation)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Routine GDM screening (24-28 weeks' gestation)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Early GDM screening
Number of subjects: 913

Group type: COMPARATOR
Intervention: Routine GDM screening
Number of subjects: 913
Study: 33662166

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (AHM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 36
Study: 36321501

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 12 months
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo-matched tablet
Number of subjects: 280
Study: 33996262

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 32697957

Group type: EXPERIMENTAL
Intervention: Repetitions to failure (RFG, n = 13)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Repetitions not to failure and 50% of the repetitions of the RFG (NFG, n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Repetitions not to failure with equal training volume of the RFG (ENFG, n = 11)
Number of subjects: 36
Study: 34563558

Group type: EXPERIMENTAL
Intervention: Crystalloid fluid at 10 mL.kg‐1 of ideal body weight administered intravenously 30 minutes before BCP
Number of subjects: 49
Study: 32048881

Group type: EXPERIMENTAL
Intervention: 24-hour dietary recall
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Nutrient adequacy ratios from 3-day weighed food records
Number of subjects: 468
Study: 35102001

Group type: EXPERIMENTAL
Intervention: Structured contraceptive counselling
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Standard contraceptive counselling
Number of subjects: 1295
Study: 34772367

Group type: EXPERIMENTAL
Intervention: Intervention (PeARS): one antenatal and one postnatal session including support from a non-professional peer, information about local community services, and development of a personalised If-Then plan.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (booklet about local resources)
Number of subjects: 126
Study: 32921170

Group type: EXPERIMENTAL
Intervention: 23 autosomal STR markers genotyping using PowerPlex® Fusion 6C multiplex system (Promega)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Genetic relatedness analysis with non-Muslim populations
Number of subjects: 184
Study: 35171948

Group type: EXPERIMENTAL
Intervention: Family-centered psychoeducational intervention (fertility preservation values clarification tool and guided conversation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care control group (fertility consult)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-centered psychoeducational intervention
Number of subjects: 0
Study: 34328655

Group type: EXPERIMENTAL
Intervention: Parametric knockoff filter based on variable importance scores from penalized linear regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric knockoff filter based on causal forest variable importance scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of proposed methods to data from a randomized clinical trial
Number of subjects: 0
Study: 32583773

Group type: EXPERIMENTAL
Intervention: Probiotic treatment T2 (6 billion cfu)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probiotic treatment T1 (3 billion cfu)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phase-III (Plumpy'nut)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 30
Study: 34562410

Group type: EXPERIMENTAL
Intervention: Various treatment strategies for MINOCA (specifics not provided)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing)
Number of subjects: 150
Study: 33760658

Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 308
Study: 34590519

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 33068347

Group type: EXPERIMENTAL
Intervention: Medicated plaster at Dazhui (GV 14) applied 30 min before operation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group received routine heat preservation measures
Number of subjects: 300
Study: 35606688

Group type: EXPERIMENTAL
Intervention: Postoperative depression
Number of subjects: 320

Group type: COMPARATOR
Intervention: Baseline depression
Number of subjects: 320
Study: 33065191

Group type: COMPARATOR
Intervention: HCS-only
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HCS+PAE
Number of subjects: 117
Study: 32567586

Group type: EXPERIMENTAL
Intervention: Preparation with polyethylene glycol (PEG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Preparation with sodium picosulfate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up phone call prior to the study
Number of subjects: 100
Study: 36266046

Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment with usual care
Number of subjects: 813

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 813
Study: 34819291

Group type: EXPERIMENTAL
Intervention: Arm 1: Reminder texts and US$0.50 per day of medication taken
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm 2: US$0.25 per adherent-day with adaptive reward system and reminder texts if adherence <75%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control: Not specified
Number of subjects: 0
Study: 32250059

Group type: EXPERIMENTAL
Intervention: Psilocybin (0.3 to 0.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supraclinical psilocin (60 ng/mL)
Number of subjects: 0
Study: 32315508

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gla-300 and IDeg
Number of subjects: 0
Study: 35124734

Group type: EXPERIMENTAL
Intervention: Robotic-assisted RP
Number of subjects: 310
Study: 34091625

Group type: EXPERIMENTAL
Intervention: Education through specifically-designed tools
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study: 32811527

Group type: EXPERIMENTAL
Intervention: Periacetabular Osteotomy with hip arthroscopy (experimental group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isolated Periacetabular Osteotomy (control group)
Number of subjects: 52
Study: 35952408

Group type: EXPERIMENTAL
Intervention: Locomotion training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 32522756

Group type: EXPERIMENTAL
Intervention: agalsidase‐beta (1.0 mg/kg), regular‐dose group, n=17
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: agalsidase‐alfa (0.2 mg/kg), switch group, n=22
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: agalsidase‐beta after agalsidase‐alfa, re‐switch group, n=39
Number of subjects: 78
Study: 32888906

Group type: EXPERIMENTAL
Intervention: Self-regulated dual task (mathematical task) during prone bridging test
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Self-regulated dual task (mathematical task) during Biering-Sorensen test
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single task (without cognitive condition) during Biering-Sorensen test
Number of subjects: 14
Study: 34528692

Group type: EXPERIMENTAL
Intervention: 8-session telehealth intervention for speech-language therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engaged communication partner group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Check-in group (randomized control)
Number of subjects: 0
Study: 32203040

Group type: EXPERIMENTAL
Intervention: Automated Brain Metastases Detection Framework using gadolinium-enhanced T1-weighted 3D MRI
Number of subjects: 158

Group type: COMPARATOR
Intervention: State-of-the-art approaches for larger lesions
Number of subjects: 158
Study: 35944873

Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes (CMFD) intervention
Number of subjects: 13
Study: 33823208

Group type: EXPERIMENTAL
Intervention: Low temperature (4 °C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Room temperature (25 °C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Warmed (37 °C)
Number of subjects: 80
Study: 32384426

Group type: EXPERIMENTAL
Intervention: Sirolimus tablet (NPC‐12T)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34056830

Group type: EXPERIMENTAL
Intervention: JW-100 (CBD plus aspartame)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CBD only
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 32667956

Group type: EXPERIMENTAL
Intervention: Modified Otago Exercise Program (home-based balance and strength exercises)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-exercise group (continuation of usual lifestyle)
Number of subjects: 52
Study: 34282872

Group type: EXPERIMENTAL
Intervention: Integrated low-intensity intervention program (additional visits, health education, enhanced communication, weekly SMS reminders)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 172
Study: 33334875

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 32543698

Group type: EXPERIMENTAL
Intervention: Spiritual experiences, values, and beliefs; religious practices; overall self‐ranking of spirituality's importance
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Feeling God's presence daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Considering oneself very religious
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Considering oneself very spiritual
Number of subjects: 126

Group type: COMPARATOR
Intervention: Spiritual scales
Number of subjects: 126
Study: 36137472

Group type: EXPERIMENTAL
Intervention: OS + NNS
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: OS + NNS + T/K
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 33563321

Group type: EXPERIMENTAL
Intervention: 5-oxoproline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dihomo-linoleate (20:2n6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p-acetamidophenylglucuronide
Number of subjects: 0
Study: 35396297

Group type: COMPARATOR
Intervention: 5 µg vaccine (Stage I)
Number of subjects: 368

Group type: COMPARATOR
Intervention: 3 µg vaccine (Stage I)
Number of subjects: 368

Group type: COMPARATOR
Intervention: 5 µg vaccine (Stage II)
Number of subjects: 368

Group type: COMPARATOR
Intervention: 5 µg vaccine (Phase II)
Number of subjects: 368

Group type: COMPARATOR
Intervention: cVNT (Phase I)
Number of subjects: 368

Group type: COMPARATOR
Intervention: cVNT (Phase II)
Number of subjects: 368
Study: 35301422

Group type: EXPERIMENTAL
Intervention: Icon
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Clinpro with HCl pretreatment
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Phosphoric acid (PA) + Clinpro
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Phosphoric acid (PA) + Aegis
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (HCl) + Clinpro
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (HCl) + Aegis
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control
Number of subjects: 174
Study: 32445498

Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg monthly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg quarterly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35793879

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study: 33737422

Group type: EXPERIMENTAL
Intervention: eCDS tool for suspected cancer
Number of subjects: 530

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 530
Study: 32433779

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily
Number of subjects: 244
Study: 35608178

Group type: EXPERIMENTAL
Intervention: FAST simulator training (low-fidelity)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experimental group (FAST simulator training)
Number of subjects: 28
Study: 32931877

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alfa2a (PEG‐IFN) treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (patients without HBsAg loss)
Number of subjects: 83
Study: 35693746

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose: 1 μg/kg over 10 min; maintenance dose: 0.2‐0.7 μg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (loading dose: 75 μg/kg over 10 min; maintenance dose: 12.5‐75 μg/kg/min)
Number of subjects: 40
Study: 32780820

Group type: EXPERIMENTAL
Intervention: Trephine drill
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 42
Study: 34476645

Group type: EXPERIMENTAL
Intervention: Reparixin (R) in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Reparixin (R) + paclitaxel (P)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo + paclitaxel (P)
Number of subjects: 123
Study: 32712017

Group type: EXPERIMENTAL
Intervention: SAPIEN XT transcatheter heart valve (THV)
Number of subjects: 199
Study: 35333027

Group type: EXPERIMENTAL
Intervention: FIVE futsal neuromuscular warm-up program, performed 3 times per week for 6 weeks, in addition to regular futsal training.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular futsal training only (Control group).
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: FIVE futsal neuromuscular warm-up program.
Number of subjects: 95